Table 6.
Simple main effect analysis of CYP2D6 and CYP3A5 phenotypes on MR (TAM-4OHT)
| Gene polymorphisms | n | p | Gene polymorphisms | n | p | ||
|---|---|---|---|---|---|---|---|
| CYP3A5-EM | CYP2D6-EM | 31 | 0.176 | CYP2D6-EM | CYP3A5-EM | 31 | 0.671 |
| CYP2D6-IM | 51 | CYP3A5-PM | 24 | ||||
| CYP2D6-PM | 0 | CYP2D6-IM | CYP3A5-EM | 51 | 0.778 | ||
| CYP3A5-PM | CYP2D6-EM | 24 | 0.056 | CYP3A5-PM | 25 | ||
| CYP2D6-IM | 25 | CYP2D6-PM | CYP3A5-EM | 0 | Unable to compute | ||
| CYP2D6-PM | 2 | CYP3A5-PM | 2 |
Notes: The concentrations of TAM and its metabolites are presented as median (interquartile range). p=p value from Kruskal–Wallis test.
Abbreviations: 4OHT, 4-hydroxytamoxifen; EM, extensive metabolizer; IM, intermediate metabolizer; MR, metabolic ratios; PM, poor metabolizer; TAM, tamoxifen.